Podcast
MSL Talk: Tom Caravela
What Makes KOLs Tick
Summary
In this episode, Deanna Murray joins to delve into the intricacies of engaging with Key Opinion Leaders (KOLs). The discussion begins with understanding KOL motivations and the importance of aligning with their needs. Deanna highlights the significance of proactive strategies, effective pre-call planning, and questioning techniques. The conversation explores innovative approaches to KOL engagement, emphasizing problem-solving and tailoring presentations. The role of MSLs in rare diseases and adapting to hybrid interactions post-COVID are also covered. The episode concludes with performance enhancement tips and an acknowledgment of the sponsor, High Five Challenge.
Deanna Murray, MSL Team Lead at Sarepta Pharmaceuticals discusses what makes KOLs tick and how to be a more effective MSL
Deanna shares…
👉 How to be a more proactive MSL vs reactive
👉 What questions MSLs should be asking their KOLs
👉 Why pre-call planning is so important
👉 How to determine WHAT you should be presenting to your KOLs
👉 Creative ways to get face time with your KOLs
Key Opinion Leaders, KOL engagement strategies, proactive MSL techniques, rare disease MSL roles, hybrid interaction post-COVID
Related Topics
You May Also Like
MSL Talk: Tom Caravela
Podcast
MSL Talk: Tom Caravela, Linda Taylor
The 3 “Knows” of Effective Scientific Communication
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary